Our rapid COVID-19 tests and NAVICA system work together as a comprehensive solution to easily view, share, confirm and manage COVID-19 test results.
If you have a BinaxNOW™ COVID-19 Ag Card Home Test, join an eMed session for live testing support with a certified guide.
To minimize the spread of COVID-19, we have completely rethought our daily routines. We work from home. We learn remotely. We socialize outdoors. We second guess many of the places we go.
Abbott has designed and optimized our rapid COVID-19 tests for use in a variety of settings, including urgent care clinics, physician offices, schools, workplaces, and in the comfort of home. Testing, when used in combination with protective measures including COVID-19 vaccines, mask wearing, hand washing, and social distancing, is key to recovery from the COVID-19 pandemic.
The NAVICA™ System provides a comprehensive digital platform for supporting COVID-19 testing. It includes a suite of mobile applications and an easy-to-use online portal that work with Abbott rapid COVID-19 tests to help individuals and organizations make informed decisions with greater confidence.
Download the NAVICA app, then take an Abbott rapid COVID-19 test at a NAVICA-enabled testing site or at home. The tests use a nasal swab and provide results in 15 minutes.
Receive a notification when test results are available to view in the NAVICA app. A negative test result automatically generates an encrypted NAVICA Pass. If the test is positive, the participant is advised to contact their healthcare provider, quarantine and follow CDC guidelines.
Display a NAVICA Pass, similar to an airline boarding pass, at NAVICA-enabled environments such as office buildings and schools to verify a recent negative test for COVID-19.
Organizations such as employers or schools can use NAVICA to support their COVID-19 testing programs.
The BinaxNOW COVID-19 Ag Card and the BinaxNOW COVID-19 Ag Card Home Test have received Emergency Use Authorization by the U.S. Food and Drug Administration. Both tests work with the NAVICA system to provide fast, reliable results that can be displayed in the NAVICA app.
BinaxNOW™ COVID-19 Ag Card is a rapid, reliable, highly portable, and affordable antigen test for detecting active coronavirus infections in 15 minutes.
The BinaxNOW™ COVID-19 Ag Card Home Test, The NAVICA app, and eMed digital health solution provide peace of mind with reliable, rapid testing in the safety and convenience of home.
NAVICA, the first-of-its-kind app, can be downloaded from both
the App Store® and Google Play™ at no charge. Go to your app
store and search NAVICA to download the NAVICA app.
Our widely used BinaxNOW COVID-19 Ag Card can now be used at
home with a prescription through a virtually guided online service.
Learn more in the NAVICA app.
NAVICA will display a digital NAVICA Pass via a QR code, similar to an airline boarding pass, for the NAVICA user who has received a negative result from a NAVICA-enabled test site. This allows organizations to verify negative test results, enabling people to move about with greater confidence, or see a positive test result and request that the person self-quarantine to avoid infecting others.
Getting a NAVICA pass is an easy 3-step process:
The BinaxNOW COVID-19 Ag Card is a rapid lateral flow antigen test administered by a healthcare professional or a trained operator. It tests for active infection using a direct nasal swab. It provides a positive or negative result in 15 minutes with no instrument required.
Our technical services team can be reached Monday to Friday 8AM to 8PM Eastern Standard Time at (800) 257-9525. Please have the following information available so we can best assist you: phone type, phone operating version, and app version.
Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.
The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Based on your current location, the content on this page may not be relevant for your country.
